# Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes

Study · id `cardio:ct-nct01313533` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01313533](<https://clinicaltrials.gov/study/NCT01313533>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01313533

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 540 participants.

## Technical summary

Registry record NCT01313533. Randomized; quadruple masking; primary purpose prevention. Start 2015-03 (registry gives no type); primary completion 2019-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 1/2
- Enrolled: 540 participants (planned count; ClinicalTrials.gov record NCT01313533, source copy `cardio:ctgov-nct01313533-2019-04-04`, retrieved 2026-10-31)
- Start date: 2015-03 (registry gives no type) (ClinicalTrials.gov record NCT01313533, source copy `cardio:ctgov-nct01313533-2019-04-04`, retrieved 2026-10-31)
- Primary completion: 2019-12 (anticipated) (ClinicalTrials.gov record NCT01313533, source copy `cardio:ctgov-nct01313533-2019-04-04`, retrieved 2026-10-31)
- Completion: 2021-11 (anticipated) (ClinicalTrials.gov record NCT01313533, source copy `cardio:ctgov-nct01313533-2019-04-04`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01313533, source copy `cardio:ctgov-nct01313533-2019-04-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01313533-2019-04-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes
- Condition: Atherosclerosis
- Intervention (Drug): Polyarginine
- Intervention (Drug): Vein soak treated with Lactated Ringers Solution
- Lead sponsor: St. Luke's Hospital, Chesterfield, Missouri
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)

## Provenance

Content hash: 3aab8feee1fd686494262f01f5045bc832072b4d33164289a21be46211faf121
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
